<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>PHARMACOVIGILANCE</title>
    <link rel="stylesheet" href="1stsem.css">
</head>
<nav class="navbar">
    <div class="home"> <a href="index.html">Home</a></div>
    <div class="news"><a href="news.html">News</a></div>
    <div class="about"><a href="about.html">About</a></div>
    <div class="contact"><a href="contact.html">Contact</a></div>
 </nav>
<body>
    <header><H1><b><marquee>Pharma Tube</marquee></b></H1>
        <h3>Learn Well Earn Well</h3> </header>

        <main>
            <section>
                <p class="nameofsubject">PHARMACOVIGILANCE</p>
                <div class="hap">
                    <b><u><i> UNIT-1 </i></u></b>
                    <b>Introduction to Pharmacovigilance</b>
                     Historyand development of Pharmacovigilance<br>
                   Importance of safety monitoring of Medicine<br>
                   WHOinternational drug monitoring programme<br>
                   Pharmacovigilance Programof India(PvPI)<br>
                    <b> Introduction to adverse drug reactions</b>

                    Definitions and classification of ADRs <br>
                     Detection and reporting <br>
                     MethodsinCausality assessment  <br>
                     Severityand seriousness assessment <br>
                     Predictability and preventability assessment <br>
                     Management of adverse drugreactions <br>
                    <b>Basic terminologies used in pharmacovigilance</b>
                    Terminologies of adverse medication related events<br>
  Regulatoryterminologies
                   
                     <a href="" download="PH. VIGILANCE unit-1" target="blank"  rel="norefferance"> UNIT-1 (Download)  </a><div> <hr> </div>



                     <b><u><i> UNIT-2 </i></u></b>
                     <b> Drug and disease classification </b>
                     Anatomical, therapeutic and chemical classification of drugs<br>
 International classification of diseases<br>
 Dailydefined doses<br>
 International Non proprietary Names for drugs<br>



                     <b> Drug dictionaries and coding in pharmacovigilance</b>


                      WHOadversereactionterminologies<br>
 MedDRAandStandardised MedDRA queries<br>
 WHOdrugdictionary<br>
 Eudravigilance medicinal product dictionary<br>


                     <b>Information resources in pharmacovigilance</b>
                     Basicdruginformation resources<br>Specialised resources for ADRs <br>



                     <b>Establishing pharmacovigilance programme</b>


                     Establishing in a hospital<br>
                     Establishment & operation of drug safety partment in industry<br>
                     Contract Research Organisations (CROs)<br>
                     Establishing a national programme<br>
                  
                     <a href="" download="PH. VIGILANCE unit-2" target="blank"  rel="norefferance"> UNIT-2 (Download) </a><div> <hr> </div>




                     <b><u><i> UNIT-3 </i></u></b>
                     <b>Vaccine safety surveillance</b>

                     Vaccine Pharmacovigilance<br>
  Vaccination failure<br>
  Adverse events following immunization<br>


                     <b>Pharmacovigilance methods</b>


                     Passive surveillance– Spontaneous reports and case series<br>
  Stimulated reporting<br>
  Active surveillance– Sentinel sites, drug event monitoring and registries<br>
  Comparative observational studies– Cross sectional study, case control study and
 cohort study<br>
  Targeted clinical investigations <br>





                     <b> Communication in pharmacovigilance </b>

                      Effective communication in Pharmacovigilance<br>
  Communication in DrugSafety Crisis management<br>
  Communicatingwith Regulatory Agencies, Business Partners, Healthcare facilities &
 Media<br>
                    
                     <a href="" download="PH. VIGILANCE unit-3" target="blank"  rel="norefferance"> UNIT-3 (Download) </a><div> <hr> </div>






                     <b><u><i> UNIT-4 </i></u></b>
                     <b> Safety data generation</b>

                      Preclinical phase<br>
  Clinical phase<br>
  Postapproval phase (PMS)<br>


                     <b>ICH Guidelines for Pharmacovigilance</b>


                      Organization and objectives of ICH<br>
                      Expedited reporting<br>
                      Individual case safety reports<br>
                      Periodic safety update reports<br>
                      Postapproval expedited reporting<br>
                      Pharmacovigilance planning<br>
                      Goodclinical practice in pharmacovigilance studies<br>
                    
                     <a href="" download="PH. VIGILANCE unit-4" target="blank"  rel="norefferance"> UNIT-4 (Download) </a><div> <hr> </div>






                     <b><u><i> UNIT-5 </i></u></b>
                     <b> Pharmacogenomics of adverse drug reactions</b>Genetics related ADR with example focusing PK parameters.
                     <b>Drug safety evaluation in special population</b>Paediatrics<br>
                      Pregnancyand lactation<br>
                      Geriatrics<br>


                     <b> CIOMS</b>
                     CIOMS WorkingGroups<br>
                      CIOMS Form <br>


                     <b>CDSCO (India) andPharmacovigilance</b>

                     D&CActandScheduleY<br>
  Differences in Indian and global pharmacovigilance requirements<br>
                     <b></b>
                     <b></b>
                     <b></b>
                     <a href="" download="PH. VIGILANCE unit-5" target="blank"  rel="norefferance"> UNIT-5  (Download)


                </div> 

            </section>
        </main>





        <footer><p class="foot"> © 2024 Pharma Tube. All rights reserved.</p></footer>

           
</body>
</html>